Citations

Clear

1446 citation(s) found for "Howard, F".

Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study
Neal‐Perry, Genevieve , Pal, Lubna , Løbo, Rogerio A. , Black, Dennis M. , Budoff, Matthew J. , Cedars, Marcelle I. , Dowling, N. Maritza , Dunn, Mary Hunzicker, Gleason, Carey E. , Hodis, Howard N., Isaac, Barbara, Magnani, Maureen, Miller, Virginia M. , Taylor, Hugh S. , Wharton, Whitney , Wolff, E.F., Zepeda, Viola, Harman, S. Mitchell , Santoro, Nanette, Santoro, Nanette F. , Allshouse, Amanda A. , Naftolin, Frederick , Brinton, Eliot A. , Manson, JoAnn E. , Budoff, Matthew

Mayo Clinic

Menopause | October 25, 2016 | Volume: 24 | Issue: 3 | Pages: 238-246

10.1097/gme.0000000000000756 | PMID 27779568 Get It

Abstract Objective: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. Methods: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E 2 ) 50 μg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275). Menopausal symptoms were recorded at screening and at 6, 12, 24, 36, and 48 months postrandomization. Differences in proportions of women with symptoms at baseline and at each follow-up time point were compared by treatment arm using exact χ 2 tests in an intent-to-treat analysis. Differences in treatment effect by race/ethnicity and body mass index were tested using generalized linear mixed effects modeling. Results: Moderate to severe hot flashes (from 44% at baseline to 28.3% for PBO, 7.4% for t-E 2 , and 4.2% for o-CEE) and night sweats (from 35% at baseline to 19% for PBO, 5.3% for t-E 2 , and 4.7% for o-CEE) were reduced significantly by 6 months in women randomized to either active hormone compared with PBO ( P < 0.001 for both symptoms), with no significant differences between the active treatment arms. Insomnia and irritability decreased from baseline to 6 months postrandomization in all groups. There was an intermittent reduction in insomnia in both active treatment arms versus PBO, with o-CEE being more effective than PBO at 36 and 48 months ( P = 0.002 and 0.05) and t-E 2 being more effective than PBO at 48 months ( P = 0.004). Neither hormone treatment significantly affected irritability compared with PBO. Symptom relief for active treatment versus PBO was not significantly modified by body mass index or race/ethnicity. Conclusions: Recently postmenopausal women had similar and substantial reductions in hot flashes and night sweats with lower-than-conventional doses of oral or transdermal estrogen. These reductions were sustained during 4 years. Insomnia was intermittently reduced compared with PBO for both hormone regimens.
Sex Differences in Fractional Flow Reserve-Guided Revascularization: A Nationwide Analysis
Lakhter, Vladimir , Zack, Chad, Cohen, Howard, O’Neill, Brian P. , O’Murchu, Brian, Bové, Alfred A., Bashir, Riyaz , Zack, Chad J, Alkhouli, Mohamad , Zhao, Huaqing

Mayo Clinic

Journal of Women's Health | October 18, 2016 | Volume: 26 | Issue: 2 | Pages: 109-115

10.1089/jwh.2016.5806 | PMID 27754754 Get It

P4‐108: Leptin, Adiponectin and Cognition in Middle‐Aged Hiv‐Infected and Uninfected Women: The Brooklyn Women’s Interagency HIV Study
Gustafson, Deborah , Holman, Susan, Crystal, Howard, Mielke, Michelle M. , Keating, Sheila M. , MINKOFF, HOWARD L.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_22 | Pages: No page available

10.1016/j.jalz.2016.06.2199 Get It

Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease
Goodwin, Emily F., Partain, Paige , Fineberg, Naomi S., Howard, Thomas H., Partain, Paige I, Lebensburger, Jeffrey D. , Partain, Paige

Mayo Clinic

Pediatric Blood & Cancer | September 19, 2016 | Volume: 64 | Issue: 1 | Pages: 113-120

10.1002/pbc.26179 | PMID 27643455 Get It

AbstractBackgroundCholelithiasis is a frequent complication in pediatric sickle cell disease (SCD). Though it is standard practice to perform a cholecystectomy in pediatric SCD patients with symptoms of cholelithiasis, the use of elective cholecystectomy for asymptomatic patients remains controversial.ProcedureRecords of 191 pediatric sickle cell patients with cholelithiasis who underwent cholecystectomy were retrospectively reviewed. Patients classified as follows: (i) elective—no preoperative symptoms, cholelithiasis on screening ultrasound, comprehensive preoperative plan; (ii) symptomatic—preoperative symptoms of cholelithiasis on diagnostic ultrasound, comprehensive preoperative plan; or (iii) emergent—hospitalization for acute cholecystitis symptoms, cholelithiasis on diagnostic ultrasound, limited preoperative preparation. We compared the morbidity of cholecystectomy by examining pre‐ and post‐cholecystectomy hospital admission days, length of stay for cholecystectomy, and surgical complications.ResultsPatients with SCD underwent a total of 191 cholecystectomies over a 10‐year period: 51 elective, 110 symptomatic, and 30 emergent. Patients who required emergent cholecystectomy had a longer postoperative hospitalization time than elective or symptomatic cholecystectomy (7.3 vs 4.3, P < 0.001). Baseline values for total bilirubin and aspartate aminotransferase (AST) were significantly elevated (P < 0.02 and P < 0.07, respectively) in patients requiring emergent cholecystectomy.ConclusionsThis represents the largest reported retrospective review of pediatric cholelithiasis and cholecystectomy in SCD to date. These data strongly suggest that elective cholecystectomy decreases morbidity associated with emergent cholecystectomy. The overall outcomes for symptomatic and elective patients are favorable. However, our study indicates the need for prospective studies to identify clinical indicators for those emergent patients.
Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
Wang, Zhaoming , Obazee, Ofure , Jia, Jinping , Childs, Erica J., Hoskins, Jason W. , Figlioli, Gisella , Collins, Irene , Chung, Charles C., Hautman, Christopher, Arslan, Alan A. , Bracci, Paige M. , Buring, Julie E. , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Kamineni, Aruna , Kolonel, Laurence N. , Kulke, Matthew H. , Malats, Núria , Olson, Sara H. , Sesso, Howard D. , Visvanathan, Kala , Zheng, Wei , Abnet, Christian C. , Andreotti, Gabriella , Bueno-de-Mesquita, H. Bas, Basso, Daniela , Berndt, Sonja I. , Brenner, Hermann , Burdette, Laurie , Campa, Daniele , Caporaso, Neil E. , Capurso, Gabriele , Cavestro, Giulia Martina , Costello, Eithne , Elena, Joanne W. , Boggi, Ugo , Gaziano, J. Michael , Giovannucci, Edward L. , Gross, Myron D., Haiman, Christopher A. , Hassan, Manal M. , Helzlsouer, Kathy J., Hu, Nan , Hunter, David J., Iskierka‐Jazdzewska, Elżbieta , Jenab, Mazda , Klein, Eric A. , Krogh, Vittorio , Kupčinskas, Juozas , Kurtz, Robert C. , Landi, Maria Teresa , Mambrini, Andrea , Neale, Rachel Ε. , Oberg, Ann L. , Patel, Alpa V. , Peeters, Petra H., Peters, Ulrike , Pezzilli, Raffaele , Porta, Miquel , Purdue, Mark P. , Quirós, J. Ramón , Ríboli, Elio , Rothman, Nathaniel , Scarpa, Aldo , Scélo, Ghislaine , Strobel, Oliver , Małecka‐Panas, Ewa , Tavano, Francesca , Travis, Ruth C. , Thornquist, Mark, Tjønneland, Anne , Trichopoulos, Dimitrios, Vashist, Yogesh K. , Vodička, Pavel , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Li, Donghui , Fuchs, Charles S. , Hoover, Robert N. , Hartge, Patricia, Petersen, Gloria M. , Stolzenberg-Solomon, Rachael S., Wolpin, Brian M. , Kraft, Peter , Canzian, Federico , Ámundadóttir, Laufey T. , Zhang, Mingfeng , Mocci, Evelina , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , White, Emily , Albanes, Demetrius , Brais, Lauren K , Boutron‐Ruault, Marie‐Christine , Bijlsma, Maarten F. , Cotterchio, Michelle , Gazouli, Maria , Goggins, Michael , Kaaks, Rudolf , Key, Tim , Khaw, Kay‐Tee , Kogevinas, Manolis , Kupcinskas, Juozas , Landi, Stefano , Marchand, Loı̈c Le , Männistö, Satu , Milne, Roger L. , Panico, Salvatore , Shu, Xiao‐Ou , Silverman, Debra T. , Souček, Pavel , Sund, Malin , Taylor, Philip R. , Tobias, Geoffrey S. , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Chanock, Stephen Jacob , Klein, Alison P. , Amundadottir, Laufey , Malats, Nuria , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Travis, Ruth C , Wang, Zhaoming , Abnet, Christian C , Visvanathan, Kala , Klein, Eric A , Brenner, Hermann , Strobel, Oliver , Jenab, Mazda , Kraft, Peter , Zheng, Wei , Iskierka-Jazdzewska, Elżbieta , Riboli, Elio , Vodicka, Pavel , Neale, Rachel E , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Hoskins, Jason W , Tavano, Francesca

Mayo Clinic

Oncotarget | September 16, 2016 | Volume: 7 | Issue: 41 | Pages: 66328-66343

10.18632/oncotarget.11041 | PMID 27579533 Get It

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
Rand, Kristin A. , Song, Chi , Déan, Eric, Serie, Daniel, Curtin, Karen , Sheng, Xin , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Tomasson, Michael H. , Pawlish, Karen , Peters, Edward , Stram, Alex , Edlund, Christopher K., Conti, David V. , Zimmerman, Todd M., Hwang, Amie E. , Huntsman, Scott , Graff, John, Kong, Yinfei , Pregja, Silvana, Berndt, Sonja I. , Blot, William J. , Carpten, John D. , Chu, Lisa W., Diver, W. Ryan , Stevens, Victoria L. , Lieber, Michael R. , Goodman, Phyllis J. , Hennis, Anselm , Hsing, Ann W. , Mehta, Jayesh, Klein, Eric A. , Leske, Cristina, Murphy, Adam B. , Nemesure, Barbara , Strom, Sara S., Vij, Ravi , Rybicki, Benjamin A. , Stanford, Janet L. , Signorello, Lisa B., Witte, John S. , Bhatti, Parveen , Hu, Jennifer J. , Nyante, Sarah J. , Birmann, Brenda M. , Atanackovic, Djordje , Glenn, Martha, Jones, Brandt, Tricot, Guido , Kumar, Shaji , Wolf, Jeffrey L. , Halverson, Sandra L. , Rothman, Nathaniel , Brooks‐Wilson, Angela , Kolonel, Laurence N. , Severson, Richard K., Janakiraman, Nalini, Terebelo, Howard R. , Brown, Elizabeth E. , Roos, Anneclaire J. De , Mohrbacher, Ann , Spinelli, John J. , Munshi, Nikhil C. , Levy, Joan, Zonder, Jeffrey A. , Orlowski, Robert Z. , Camp, Nicola J. , Vachon, Celine M. , Ziv, Elad , Hazelett, Dennis J. , Haiman, Christopher A. , Serie, Daniel J, Hu, Donglei , Ailawadhi, Sikander , Singhal, Seema , Bock, Cathryn Hufford , Berg, David Van Den , Nooka, Ajay K. , Casey, Graham , Kittles, Rick A. , Kolb, Suzanne , Neslund-Dudas, Christine M , Ambrosone, Christine B. , John, Esther M. , Bernstein, Leslie , Zheng, Wei , Olshan, Andrew F. , Ziegler, Regina G. , Bandera, Elisa V. , Ingles, Sue A. , Press, Michael F. , Cannon‐Albright, Lisa , Martin, Thomas G. , Rothman, Nathaniel , Rajkumar, S. Vincent , Chanock, Stephen Jacob , Slager, Susan L. , Colditz, Graham A. , Giles, Graham G. , Chiu, Brian C.‐H. , Anderson, Kenneth C. , Orlowski, Robert Z. , Lonial, Sagar , Vachon, Celine M. , Stram, Daniel O. , Cozen, Wendy , Hazelett, Dennis J , Brooks-Wilson, Angela R , Klein, Eric A , De Roos, Anneclaire J , Nyante, Sarah , Bhatti, Parveen , Birmann, Brenda M , Ziv, Elad , Conti, David V

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 2, 2016 | Volume: 25 | Issue: 12 | Pages: 1609-1618

10.1158/1055-9965.epi-15-1193 | PMID 27587788 Get It

Abstract Background: Genome-wide association studies (GWAS) in European populations have identified genetic risk variants associated with multiple myeloma. Methods: We performed association testing of common variation in eight regions in 1,318 patients with multiple myeloma and 1,480 controls of European ancestry and 1,305 patients with multiple myeloma and 7,078 controls of African ancestry and conducted a meta-analysis to localize the signals, with epigenetic annotation used to predict functionality. Results: We found that variants in 7p15.3, 17p11.2, 22q13.1 were statistically significantly (P &lt; 0.05) associated with multiple myeloma risk in persons of African ancestry and persons of European ancestry, and the variant in 3p22.1 was associated in European ancestry only. In a combined African ancestry–European ancestry meta-analysis, variation in five regions (2p23.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) was statistically significantly associated with multiple myeloma risk. In 3p22.1, the correlated variants clustered within the gene body of ULK4. Correlated variants in 7p15.3 clustered around an enhancer at the 3′ end of the CDCA7L transcription termination site. A missense variant at 17p11.2 (rs34562254, Pro251Leu, OR, 1.32; P = 2.93 × 10−7) in TNFRSF13B encodes a lymphocyte-specific protein in the TNF receptor family that interacts with the NF-κB pathway. SNPs correlated with the index signal in 22q13.1 cluster around the promoter and enhancer regions of CBX7. Conclusions: We found that reported multiple myeloma susceptibility regions contain risk variants important across populations, supporting the use of multiple racial/ethnic groups with different underlying genetic architecture to enhance the localization and identification of putatively functional alleles. Impact: A subset of reported risk loci for multiple myeloma has consistent effects across populations and is likely to be functional. Cancer Epidemiol Biomarkers Prev; 25(12); 1609–18. ©2016 AACR.
Carotid Stenting Versus Carotid Endarterectomy: What Did the Carotid Revascularization Endarterectomy Versus Stenting Trial Show and Where Do We Go From Here?
Lal, Brajesh K. , Howard, George , Brott, Thomas G. , Meschia, James F. , Howard, George

Mayo Clinic

Angiology | August 9, 2016 | Volume: 68 | Issue: 8 | Pages: 675-682

10.1177/0003319716661661 | PMID 27507736 Get It

Although rapidly expanding in its use, carotid artery stenting remains a relatively new procedure. Its growth is due, at least in part, to the perceived advantages of a less invasive technique. However, the clinical effectiveness and specific role for stenting in the treatment of carotid occlusive disease are still under evaluation. The primary aim of the randomized clinical trial, Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), was to contrast the relative efficacy of carotid stenting versus carotid endarterectomy in preventing stroke, myocardial infarction, or death during a 30-day periprocedural period or ipsilateral stroke over the follow-up period in patients with symptomatic and asymptomatic extracranial carotid stenosis. The secondary goals were to describe the differential efficacy of the 2 procedures in men and women, contrast periprocedural (30-day) morbidity and postprocedural morbidity and mortality, estimate and contrast the restenosis rates of the 2 procedures, evaluate differences in measures of health-related quality of life and cost-effectiveness, and identify subgroups of participants at differential risk of stenting or surgery. This report summarizes the results obtained from CREST with respect to its primary and secondary aims.
Arguing against the proposed definition changes of PD
Duda, John E., Ferman, Tanis J. , Goldman, Jennifer G. , Growdon, John H., Hurtig, Howard I., Kaufer, Daniel , Kantarci, Kejal , Leverenz, James B. , Lippa, Carol F. , McKeith, Ian G. , Singleton, Andrew , Taylor, Angela , Tsuang, Debby W. , Zabetian, Cyrus P. , Boeve, Bradley F. , Dickson, Dennis W. , Galasko, Douglas , Galvin, James E. , López, Oscar L. , Weintraub, Daniel , Goldman, Jennifer G , Leverenz, James B , Kantarci, Kejal , Zabetian, Cyrus P , Ferman, Tanis J

Mayo Clinic

Movement Disorders | August 5, 2016 | Volume: 31 | Issue: 11 | Pages: 1619-1622

10.1002/mds.26721 | PMID 27492190 Get It

ABSTRACT As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled “Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease.” In particular, we suggest that the 1‐year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, “PD (dementia with Lewy bodies subtype),” will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Racial differences in prostate inflammation: results from the REDUCE study
Vidal, Adriana C. , Chen, Zinan, Howard, Lauren E. , Castro‐Santamaria, Ramiro , Andriole, Gerald L. , Fowke, Jay H. , Drake, Charles G. , Nickel, J. Curtis , Freedland, Stephen J. , Moreira, Daniel M. , Taioli, Emanuela , Knudsen, Beatrice S. , Howard, Lauren E

Mayo Clinic

Oncotarget | August 3, 2016 | Volume: 8 | Issue: 42 | Pages: 71393-71399

10.18632/oncotarget.10690 | PMID 29069714 Get It